[go: up one dir, main page]

DK0721469T3 - Anti-gp39-antistoffer og anvendelse deraf - Google Patents

Anti-gp39-antistoffer og anvendelse deraf

Info

Publication number
DK0721469T3
DK0721469T3 DK94926659T DK94926659T DK0721469T3 DK 0721469 T3 DK0721469 T3 DK 0721469T3 DK 94926659 T DK94926659 T DK 94926659T DK 94926659 T DK94926659 T DK 94926659T DK 0721469 T3 DK0721469 T3 DK 0721469T3
Authority
DK
Denmark
Prior art keywords
antibodies
Prior art date
Application number
DK94926659T
Other languages
Danish (da)
English (en)
Inventor
Randolph J Noelle
Teresa M Foy
Jeffrey A Ledbetter
Alejandro Aruffo
Original Assignee
Dartmouth College
Bristol Myers Squibb Pharmaceu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26814047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0721469(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College, Bristol Myers Squibb Pharmaceu filed Critical Dartmouth College
Application granted granted Critical
Publication of DK0721469T3 publication Critical patent/DK0721469T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK94926659T 1993-09-02 1994-09-02 Anti-gp39-antistoffer og anvendelse deraf DK0721469T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11625593A 1993-09-02 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
PCT/US1994/009871 WO1995006666A1 (fr) 1993-09-02 1994-09-02 Anticorps anti-gp39 et leurs utilisations

Publications (1)

Publication Number Publication Date
DK0721469T3 true DK0721469T3 (da) 2000-05-01

Family

ID=26814047

Family Applications (2)

Application Number Title Priority Date Filing Date
DK94926659T DK0721469T3 (da) 1993-09-02 1994-09-02 Anti-gp39-antistoffer og anvendelse deraf
DK94926677T DK0721346T3 (da) 1993-09-02 1994-09-02 Fremgangsmåde til induktion af antigenspecifik T-celletolerance

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94926677T DK0721346T3 (da) 1993-09-02 1994-09-02 Fremgangsmåde til induktion af antigenspecifik T-celletolerance

Country Status (17)

Country Link
US (5) US5747037A (fr)
EP (2) EP0721346B1 (fr)
JP (3) JP3007977B2 (fr)
CN (2) CN100341896C (fr)
AT (2) ATE188487T1 (fr)
AU (2) AU696235B2 (fr)
DE (2) DE69422523T2 (fr)
DK (2) DK0721469T3 (fr)
ES (2) ES2120067T3 (fr)
FI (2) FI105528B (fr)
GR (2) GR3027658T3 (fr)
HU (2) HU220296B (fr)
IL (1) IL110855A (fr)
NO (2) NO321098B1 (fr)
NZ (3) NZ549136A (fr)
PT (1) PT721469E (fr)
WO (2) WO1995006666A1 (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
EP0721346B1 (fr) * 1993-09-02 1998-06-10 Trustees of Dartmouth College Procedes permettant d'induire la tolerance des cellules t a specificite antigenique
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
JPH08239324A (ja) * 1995-03-03 1996-09-17 Fusanori Hamashima 免疫抑制剤
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
JP4751493B2 (ja) * 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
DE19634159C1 (de) * 1996-08-23 1997-09-25 Gsf Forschungszentrum Umwelt Induktion einer Tumorimmunität durch Injektion von Hybridzellen
AU4352997A (en) * 1996-08-30 1998-03-19 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
EP0966302B1 (fr) * 1997-01-10 2007-03-14 Biogen Idec MA Inc. Procedes d'administration therapeutique de composes anti-cd40l
US6428782B1 (en) * 1997-05-23 2002-08-06 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
AU2845400A (en) * 1998-12-24 2000-07-31 Phairson Medical Inc. Treatment and prevention of immune rejection reactions
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
AU5641100A (en) * 1999-06-29 2001-01-31 University Of Massachusetts Methods for inducing t cell non-responsiveness to a tissue or organ graft
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1262194A4 (fr) * 2000-03-06 2003-05-07 Eisai Co Ltd Agents therapeutiques et prophylactiques diriges contre le syndrome des antiphospholipides
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
MXPA02010507A (es) * 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
JP2003533488A (ja) 2000-05-12 2003-11-11 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド 免疫抑制を達成するための組成物および方法
EP1299542A2 (fr) * 2000-06-06 2003-04-09 Idec Pharmaceuticals Corporation Anticorps non agonistiques diriges contre gp 39 humaine, compositions les contenant et leur utilisation therapeutique
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2413190C (fr) 2000-07-03 2009-04-07 Bristol-Myers Squibb Company Methodes de traitement de maladies rhumatismales a l'aide d'une molecule ctla4 soluble
WO2002040050A1 (fr) * 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Procedes non letaux de conditionnement de receveur en vue d'une greffe de moelle osseuse
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
EP2075256A2 (fr) 2002-01-14 2009-07-01 William Herman Ligands ciblés
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
WO2003086463A1 (fr) * 2002-04-03 2003-10-23 Keio University Remedes contre le pemphigus, contenant un antagoniste du cd40l comme principe actif
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
CN1326878C (zh) * 2003-04-29 2007-07-18 中国抗体制药有限公司 抗人非何杰金淋巴瘤嵌合抗体及其衍生物与应用
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
JP4667383B2 (ja) * 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
PL1711528T3 (pl) 2003-12-23 2012-11-30 Genentech Inc Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006081620A1 (fr) * 2005-02-02 2006-08-10 Newsouth Innovations Pty Limited Lymphocytes t cd4+ cd25+ actives par un antigene specifique
CN100423775C (zh) * 2005-04-15 2008-10-08 中国农业科学院兰州兽医研究所 牛衣原体病灭活疫苗及其制备与检验方法
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
HUE026303T2 (hu) * 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
WO2007109321A2 (fr) * 2006-03-20 2007-09-27 The Regents Of The University Of California Anticorps modifiés dirigés contre l'antigène de cellules souches prostatiques servant à cibler le cancer
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP2052076A4 (fr) 2006-08-02 2010-07-14 Newsouth Innovations Pty Ltd Procédé d'identification de cellules t cd4+cd25+ activées contre un antigène et exprimant cd8
RU2009140134A (ru) * 2007-04-23 2011-05-27 Вайет (Us) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
CA2698343C (fr) 2007-09-04 2018-06-12 The Regents Of The University Of California Anticorps d'antigene de cellule souche anti-prostate (psca) a haute affinite pour un ciblage et une detection de cancer
EP2052848A1 (fr) 2007-10-27 2009-04-29 Joint Solar Silicon GmbH & Co. KG Préparation de pièces brutes en silicium pur
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
US8911739B2 (en) 2009-02-10 2014-12-16 Trustees Of Columbia University In The City Of New York Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide
CN105837691B (zh) * 2009-03-10 2021-06-29 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
WO2013013708A1 (fr) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Traitement du rejet aigu dans une transplantation rénale
CN105722532A (zh) 2013-09-13 2016-06-29 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
TN2018000021A1 (en) 2015-07-14 2019-07-08 Immunext Inc ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY.
CA2994825A1 (fr) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anticorps anti-cd154 et procedes d'utilisation correspondant
WO2017053469A2 (fr) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Polypeptides de liaison à cd3
CA2946465C (fr) 2015-11-12 2022-03-29 Delta Faucet Company Generateur d'ozone destine a un robinet
WO2017201476A1 (fr) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Procédés pour briser la tolérance immunologique à l'aide de multiples arn de guidage
EP3630843A2 (fr) 2017-05-24 2020-04-08 ALS Therapy Development Institute Anticorps anti-ligand anti-cd40 thérapeutiques
KR102142499B1 (ko) * 2019-09-11 2020-08-10 재단법인 오송첨단의료산업진흥재단 Ykl-40 표적 인간 단일클론항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
CA2121798C (fr) * 1991-10-25 2007-07-24 Richard J. Armitage Nouvelle cytokine
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (fr) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Recepteur cd40cr et ligands pour celui-ci
WO1994004570A1 (fr) * 1992-08-21 1994-03-03 Schering Corporation Ligand cd40, anticorps anti-cd40, et cd40 soluble
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
EP0721346B1 (fr) * 1993-09-02 1998-06-10 Trustees of Dartmouth College Procedes permettant d'induire la tolerance des cellules t a specificite antigenique
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Also Published As

Publication number Publication date
HU220296B (hu) 2001-11-28
US20020187135A1 (en) 2002-12-12
NO960862D0 (no) 1996-03-01
AU7642994A (en) 1995-03-22
EP0721469B1 (fr) 2000-01-05
IL110855A0 (en) 1994-11-28
US6312692B1 (en) 2001-11-06
DK0721346T3 (da) 1999-03-22
AU696235B2 (en) 1998-09-03
JP3007977B2 (ja) 2000-02-14
FI960978L (fi) 1996-04-29
JP3098739B2 (ja) 2000-10-16
WO1995006666A1 (fr) 1995-03-09
JPH09502096A (ja) 1997-03-04
ES2120067T3 (es) 1998-10-16
EP0721346A1 (fr) 1996-07-17
CN100341896C (zh) 2007-10-10
DE69422523D1 (de) 2000-02-10
ES2143553T3 (es) 2000-05-16
AU707110B2 (en) 1999-07-01
NZ273207A (en) 1997-09-22
FI960978A0 (fi) 1996-03-01
HUT74246A (en) 1996-11-28
CN1149299A (zh) 1997-05-07
NZ273221A (en) 2001-09-28
DE69411025D1 (de) 1998-07-16
IL110855A (en) 1999-04-11
JPH11189543A (ja) 1999-07-13
NO321098B1 (no) 2006-03-20
NO960862L (no) 1996-04-30
AU7644594A (en) 1995-03-22
EP0721469A1 (fr) 1996-07-17
CN1134113A (zh) 1996-10-23
NO960861L (no) 1996-04-30
US20060222649A1 (en) 2006-10-05
HUT74250A (en) 1996-11-28
NO321036B1 (no) 2006-03-06
AU678532B2 (en) 1997-05-29
US5876718A (en) 1999-03-02
WO1995006481A1 (fr) 1995-03-09
HU218610B (hu) 2000-10-28
DE69411025T2 (de) 1999-01-07
GR3033095T3 (en) 2000-08-31
HU9600522D0 (en) 1996-04-29
FI960980A0 (fi) 1996-03-01
FI105528B (fi) 2000-09-15
ATE188487T1 (de) 2000-01-15
AU3518397A (en) 1997-10-30
PT721469E (pt) 2000-04-28
US7722874B2 (en) 2010-05-25
JP2991499B2 (ja) 1999-12-20
DE69422523T2 (de) 2000-10-12
US5747037A (en) 1998-05-05
EP0721346B1 (fr) 1998-06-10
GR3027658T3 (en) 1998-11-30
CN1127351C (zh) 2003-11-12
NZ549136A (en) 2008-02-29
JPH09502186A (ja) 1997-03-04
HU9600521D0 (en) 1996-04-29
FI106306B (fi) 2001-01-15
NO960861D0 (no) 1996-03-01
FI960980A7 (fi) 1996-04-30
ATE167062T1 (de) 1998-06-15

Similar Documents

Publication Publication Date Title
DK0721469T3 (da) Anti-gp39-antistoffer og anvendelse deraf
NO962346D0 (no) Humaniserte antistoffer og anvendelser derav
DK145493D0 (da) Antistof
NO921863D0 (no) Antistoffer og anvendelse derav
IS4481A (is) Díhýdrópyramídín og notkun þeirra
DE69416200D1 (de) Sondenkonstruktion
NO961425D0 (no) 1N-alkyl-N-arylpyrimidinaminer og derivater derav
NO943763D0 (no) 4-arylamino-benzopyraner og beslektede forbindelser
FI960803A0 (fi) TNF-alfa-sekreetion inhibiittoreita
FI945857L (fi) Immunomääritys
BR9407089A (pt) Moega e método
DE69322847D1 (de) Monoklonaler Antikörper gegen menschliches Ceruloplasmin
FI945485L (fi) Monoklonaaliset vasta-aineet ja niiden käyttö
DE69421212D1 (de) Verstärker mit sequentieller Wirkungsweise
ITMI921571A1 (it) Azaciclo e azabiciclo alchiliden idrossilamine
BR9205281A (pt) Pentapeptideos imuno-reguladores e neuro-reguladores
DE69413721D1 (de) Elektrophotographisches Gerät
DE59407860D1 (de) Prüfgerät
DE69428559D1 (de) Magnetooptisches element
DE69411051D1 (de) Elektrophotographisches Gerät
NO930418D0 (no) Innstikkbar helletut
KR950012331U (ko) 별자리 투영기
NO941791D0 (no) Biocidmateriale og anvendelse derav
DK251090D0 (da) Antistoffer og anvendelse deraf
DE69406603D1 (de) Elektrostatographisches Gerät